A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Clinical trial NCT03861793 · COMPLETED
Trial details
- NCT number
- NCT03861793
- Sponsor
- Mural Oncology, Inc
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-26
- Primary completion
- 2023-03-01
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.